APA (7th ed.) Citation

Bazarbachi, A., Galimard, J., Dalle, I. A., Socié, G., Versluis, J., Wu, D., . . . Ciceri, F. (2025). Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP. American journal of hematology, 100(8), 1374-1386. https://doi.org/10.1002/ajh.27726

Chicago Style (17th ed.) Citation

Bazarbachi, Ali, et al. "Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP." American Journal of Hematology 100, no. 8 (2025): 1374-1386. https://doi.org/10.1002/ajh.27726.

MLA (9th ed.) Citation

Bazarbachi, Ali, et al. "Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP." American Journal of Hematology, vol. 100, no. 8, 2025, pp. 1374-1386, https://doi.org/10.1002/ajh.27726.